Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Melanoma Res ; 30(6): 599-602, 2020 12.
Article in English | MEDLINE | ID: mdl-32141964

ABSTRACT

Immune checkpoint inhibitors have become the mainstay of treatment for metastatic melanoma. This article presents a new case of acquired generalised lipodystrophy (AGL) during anti-programmed cell death-1 (anti-PD-1) therapy and a systematic review of the literature with an aim to further understand the pathogenesis. A comprehensive search was conducted using PubMed, Embase, MEDLINE and Cochrane Central databases. We identified four cases of lipodystrophy associated with anti-PD-1 immunotherapy, including our own. Of these, three were associated with nivolumab, and one with pembrolizumab. Body composition changes occurred at a median of 7 months after anti-PD-1 initiation. All cases reported AGL, with subcutaneous fat loss affecting majority of the body. There were three reported cases of insulin resistance associated with AGL. AGL should be a recognised adverse event associated with anti-PD-1 therapy.


Subject(s)
Immune Checkpoint Inhibitors/adverse effects , Lipodystrophy/chemically induced , Melanoma/complications , Skin Neoplasms/complications , Female , Humans , Melanoma/drug therapy , Middle Aged , Skin Neoplasms/drug therapy
2.
Int J Womens Dermatol ; 4(1): 49-53, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29872677

ABSTRACT

Inherited and autoimmune blistering diseases are rare, chronic, and often severe disorders that have the potential to significantly affect patients' quality of life. The effective management of these conditions requires consideration of the physical, emotional, and social aspects of the disease. Self-esteem is integral to patients' ability to cope with their illness, participate in treatment, and function in society. This article discusses quality-of-life studies of patients with blistering diseases with a particular focus on self-esteem issues that patients may face.

3.
Invest Ophthalmol Vis Sci ; 56(11): 6734-9, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26567784

ABSTRACT

PURPOSE: Hemidecussation of fibers entering the optic chiasm from the optic nerves is well recognized. The reason why bitemporal hemianopia results from chiasmal compression has not been fully explained. There is still a paucity of data relating to the precise details of the routes that the nerve fibers take through the chiasm and, in particular, where and how nerve fibers cross each other. This information is important to understanding why crossing fibers are selectively damaged as a result of chiasmal compression. METHODS: An optic chiasm obtained at postmortem was fixed, stained, and sectioned to allow high-resolution photomicrographs to be taken. The photomicrographs were integrated to allow regions of interest across entire sections to be analyzed for fiber direction and crossing. RESULTS: The results confirmed that fibers from the temporal retina pass directly backward in the lateral chiasm to the optic tract, whereas fibers from the nasal retina cross to the contralateral optic tract. Crossings take place in the paracentral regions of the chiasm rather than in the center of the chiasm (where the nerve fibers are traveling mostly in parallel). The paracentral crossing regions are distributed in a largely postero-superior to antero-inferior arrangement. CONCLUSIONS: These findings clarify the precise locations and crossing angles of crossing nerve fibers in the chiasm. This information may help explain the clinical observation of junctional scotoma and will provide a much better basis for structural modeling of chiasmal compression which, in turn, will improve our understanding of how and why bitemporal hemianopia occurs.


Subject(s)
Nerve Fibers , Optic Chiasm/anatomy & histology , Photomicrography , Cadaver , Constriction, Pathologic/complications , Hemianopsia/etiology , Humans , Male , Middle Aged , Optic Chiasm/cytology
SELECTION OF CITATIONS
SEARCH DETAIL
...